Mereo Under Fire As Shareholder Unrest Erupts
Rubric Demands Board Changes
The UK biotech is developing three key assets - setrusumab, alvelestat and etigilimab - but according to its biggest stockholder, the progress being made is too slow and the share price is too low.
You may also be interested in...
The Danish biotech is looking to end 2022 on a high after raising over $105m and posting positive Phase III data on glepaglutide.
The Swedish biotech is well positioned with soon-to-be late-stage clinical assets, commercial validation and a strong pipeline, new CEO Richard Godfrey tells Scrip.
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.